ReviewVeterinary research2025
Evolutionary and structural insights into VP1 epitopes of representative SAT-type FMDV strains: implications for candidate vaccine selection.
Review in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Foot-and-mouth disease (FMD) is a highly contagious viral disease primarily affecting cloven-hoofed animals, with outbreaks causing substantial economic losses. This review summarizes the global epidemiological landscape of Southern African Territories (SAT) serotypes of FMD virus (FMDV) from 2010 to May 2025, with a particular emphasis on the topotypic diversity and transboundary spread of SAT2 strains. By integrating phylogenetic analysis and epitope characterization of the VP1 capsid protein, we provide preliminary insights into the evolutionary trajectories of SAT-type FMDVs and their implications for vaccine design. In light of the challenges posed by frequent antigenic drift and poor vaccine matching, we strictly assess the current status of commercial multivalent inactivated vaccines and recent advances in empty capsid subunit vaccine technologies. Comparative evaluation of these strategies underlines the need for enhanced molecular surveillance and rational vaccine optimization to mitigate the ongoing spread of SAT-type FMDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.